Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein

被引:277
作者
Eguchi, Akiko [1 ,2 ,3 ]
Meade, Bryan R. [1 ,2 ]
Chang, Yung-Chi [4 ]
Fredrickson, Craig T. [2 ]
Willert, Karl [2 ]
Puri, Nitin [5 ]
Dowdy, Steven F. [1 ,2 ]
机构
[1] UCSD, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA
[2] UCSD, Sch Med, Dept Cellular & Mol Med, La Jolla, CA USA
[3] Japan Soc Promot Sci, Tokyo, Japan
[4] UCSD, Sch Med, Dept Pediat, La Jolla, CA USA
[5] Life Technol, Austin, TX USA
关键词
EMBRYONIC STEM-CELLS; DOUBLE-STRANDED-RNA; CELLULAR UPTAKE; IN-VIVO; MACROPINOCYTOSIS; THERAPEUTICS; INTERFERENCE; DISEASE; GENE;
D O I
10.1038/nbt.1541
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
RNA interference (RNAi) induced by short interfering RNA (siRNA) allows for discovery research and large-scale screening(1-5); however, owing to their size and anionic charge, siRNAs do not readily enter cells(4,5). Current approaches do not deliver siRNAs into a high percentage of primary cells without cytotoxicity. Here we report an efficient siRNA delivery approach that uses a peptide transduction domain-double-stranded RNA-binding domain (PTD-DRBD) fusion protein. DRBDs bind to siRNAs with high avidity, masking the siRNA's negative charge and allowing PTD-mediated cellular uptake. PTD-DRBD-delivered siRNA induced rapid RNAi in a large percentage of various primary and transformed cells, including T cells, human umbilical vein endothelial cells and human embryonic stem cells. We observed no cytotoxicity, minimal off-target transcriptional changes and no induction of innate immune responses. Thus, PTD-DRBD-mediated siRNA delivery allows efficient gene silencing in difficult-to-transfect primary cell types.
引用
收藏
页码:567 / U110
页数:6
相关论文
共 20 条
[1]   Chemical Modification of siRNAs for In Vivo Use [J].
Behlke, Mark A. .
OLIGONUCLEOTIDES, 2008, 18 (04) :305-319
[2]   Minor-groove recognition of double-stranded RNA by the double-stranded RNA-binding domain from the RNA-activated protein kinase PKR [J].
Bevilacqua, PC ;
Cech, TR .
BIOCHEMISTRY, 1996, 35 (31) :9983-9994
[3]   Core transcriptional regulatory circuitry in human embryonic stem cells [J].
Boyer, LA ;
Lee, TI ;
Cole, MF ;
Johnstone, SE ;
Levine, SS ;
Zucker, JR ;
Guenther, MG ;
Kumar, RM ;
Murray, HL ;
Jenner, RG ;
Gifford, DK ;
Melton, DA ;
Jaenisch, R ;
Young, RA .
CELL, 2005, 122 (06) :947-956
[4]   RNAi therapeutics: a potential new class of pharmaceutical drugs [J].
Bumcrot, David ;
Manoharan, Muthiah ;
Koteliansky, Victor ;
Sah, Dinah W. Y. .
NATURE CHEMICAL BIOLOGY, 2006, 2 (12) :711-719
[5]   Interfering with disease: a progress report on siRNA-based therapeutics [J].
de Fougerolles, Antonin ;
Vornlocher, Hans-Peter ;
Maraganore, John ;
Lieberman, Judy .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (06) :443-453
[6]   TAT transduction: the molecular mechanism and therapeutic prospects [J].
Gump, Jacob M. ;
Dowdy, Steven F. .
TRENDS IN MOLECULAR MEDICINE, 2007, 13 (10) :443-448
[7]   Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells [J].
Hay, DC ;
Sutherland, L ;
Clark, J ;
Burdon, T .
STEM CELLS, 2004, 22 (02) :225-235
[8]   Preimplantation human embryos and embryonic stem cells show comparable expression of stage-specific embryonic antigens [J].
Henderson, JK ;
Draper, JS ;
Baillie, HS ;
Fishel, S ;
Thomson, JA ;
Moore, H ;
Andrews, PW .
STEM CELLS, 2002, 20 (04) :329-337
[9]   Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo [J].
Judge, AD ;
Bola, G ;
Lee, ACH ;
MacLachlan, I .
MOLECULAR THERAPY, 2006, 13 (03) :494-505
[10]   Strategies for silencing human disease using RNA interference [J].
Kim, Daniel H. ;
Rossi, John J. .
NATURE REVIEWS GENETICS, 2007, 8 (03) :173-184